DEBx Medical is poised for accelerated growth in chronic wound solutions, bolstered by the second round of investment by TVM Capital Healthcare.
AMSTERDAM and DUBAI, United Arab Emirates, Nov. 13, 2024 [...] Read more »
A DEBx Medical garante investimento expandido da TVM Capital Healthcare
A DEBx Medical está preparada para um crescimento acelerado em soluções para feridas crônicas, com o apoio da segunda rodada de investimento da TVM Capital Healthcare.
AMSTERDÃ e DUBAI, [...] Read more »
DEBx Medical obtient de nouveaux investissements auprès de TVM Capital Healthcare
Grâce au deuxième tour d’investissement de TVM Capital Healthcare, DEBx Medical s’apprête à accélérer sa croissance dans le domaine des solutions de traitement des plaies [...] Read more »
DEBx Medical sichert sich erweiterte Investition von TVM Capital Healthcare
DEBx Medical ist bereit für ein beschleunigtes Wachstum im Bereich der Lösungen für chronische Wunden, gestützt durch die zweite Investitionsrunde von TVM Capital Healthcare.
AMSTERDAM und DUBAI, [...] Read more »
EAACI to Launch World Anaphylaxis Awareness Day on 21 November at FAAM-EUROBAT 2024
ATHENS, Greece, Nov. 13, 2024 (GLOBE NEWSWIRE) — The European Academy of Allergy and Clinical Immunology (EAACI) is proud to announce the inaugural World Anaphylaxis Awareness Day on 21 [...] Read more »
ATNi Launches 5th Global Access to Nutrition Index as Industry and Policy Makers Grapple with Food Polycrisis
UTRECHT, The Netherlands, Nov. 07, 2024 (GLOBE NEWSWIRE) — Today, ATNi launches the 5th edition of the Global Access to Nutrition Index, the largest yet, assessing the world’s 30 largest food and [...] Read more »
ATNi veröffentlicht den 5. Global Access to Nutrition Index, während sich Industrie und Politik mit der Nahrungsmittelkrise als Teil der weltweiten Polykrise auseinandersetzen
UTRECHT, Niederlande, Nov. 07, 2024 (GLOBE NEWSWIRE) — ATNi veröffentlicht heute die fünfte und bisher größte Ausgabe des Global Access to Nutrition Index, der die 30 größten Lebensmittel– und [...] Read more »
ATNi lança 5º Índice Global de Acesso à Nutrição enquanto a indústria e os formuladores de políticas lutam contra a policrise alimentar
UTRECHT, Países Baixos, Nov. 07, 2024 (GLOBE NEWSWIRE) — Hoje, a ATNi lança a 5a edição do Índice Global de Acesso à Nutrição, o maior até o momento, avaliando [...] Read more »
L’ATNi lance le 5e Indice mondial d’accès à la nutrition alors que l’industrie et les décideurs politiques sont aux prises avec la polycrise alimentaire
UTRECHT, Pays–Bas, 07 nov. 2024 (GLOBE NEWSWIRE) — Aujourd’hui, l’ATNi lance la 5e édition de l’Indice mondial d’accès à la nutrition, la plus importante à ce jour. [...] Read more »
Monica Lewinsky Visits Agnivesh Agarwal’s Primeks Medical, Advocates Against Cyberbullying in Istanbul
ISTANBUL, Oct. 31, 2024 (GLOBE NEWSWIRE) — World–renowned cyberbullying activist Monica Lewinsky visited Istanbul this October at the invitation of Agnivesh Agarwal, founder of Primeks Medical Clinics and Laboratories. Her [...] Read more »
Advanced Care Group Makes a Strong Entrance at Global Health Exhibition, Ready to Lead at Arab Health 2025
RIYADH, Saudi Arabia, Oct. 25, 2024 (GLOBE NEWSWIRE) — Advanced Care Group is making waves in the Middle Eastern healthcare market following a powerful debut at the Global Health Exhibition in Riyadh. From October 21 to 23, Advanced [...] Read more »
Recursion announces first patient dosed in Phase 2 clinical study of REC-3964, a potential first-in-class, oral, non-antibiotic small molecule for recurrent Clostridioides difficile infection
- REC–3964 is Recursion’s first new chemical entity developed using the RecursionOS.
- REC–3964 represents a novel, non–antibiotic approach with a unique mechanism of action that binds and blocks [...] Read more »
Angelini Pharma Enters Into An Exclusive Option Agreement With Cureverse to License Global Development and Commercialization Rights For A Novel and Innovative Clinical-Stage Brain Health Asset
- The agreement gives Angelini Pharma an option to exclusive licensing rights to develop and commercialize CV–011, a clinical Phase 1 investigational novel compound with broad [...] Read more »
Sabin Vaccine Institute Delivers Marburg Vaccines to Combat Outbreak in Rwanda
[Caption] Sabin Vaccine Institute delivered 700 doses of its Marburg vaccine to Rwanda on Oct. 5, 2024.
WASHINGTON, Oct. 05, 2024 (GLOBE NEWSWIRE) — The Sabin Vaccine Institute has provided [...] Read more »
Recursion Announces FDA Clearance of Investigational New Drug Application for REC-1245, a Potential First-In-Class RBM39 Degrader for Biomarker-Enriched Solid Tumors and Lymphoma
- First program to combine Recursion’s end–to–end suite of AI–enabled active learning modules, resulting in target identification to IND enabling studies in under [...] Read more »